We want to save pa,ents with severe cancer and autoimmune diseases Entering clinical phase with our lead an3body CAN04 to our proprietary target

1

Göran Forsberg, CEO, August 2017

Safe Harbour Statement

Thefollowingpresenta2onmayincludepredic2ons,es2matesorotherinforma2onthatmightbeconsideredforward-looking.Thestatementsregardingthesurroundingworldandfuturecircumstancesinthispresenta2onreflectCantargia’scurrentthinkingwithrespecttofutureeventsandfinancialperformance.Prospec2vestatementsonlyexpresstheassessmentsandassump2onsthecompanymakesatthe2meofthepresenta2on.Thesestatementsarewell-considered,buttheaudienceshouldnotethat,aswithallprospec2veassessments,theyareassociatedwithrisksanduncertain2es.

2

Why invest in Cantargia? •  Focusonimmuno-oncology-thestrongestgrowingpharmaceu2calsegment

•  Takingadvantageofthewellestablishedan2bodytechnologytodesignnoveltargetedpharmaceu2cals

•  Leadcandidatean2bodyCAN04withdoublemechanismofac2onenteringclinicalstagewithmul2plevalueinflec2onpoints2017-2019•  Ini2aldevelopmentinNSCLCandpancrea2ccancer(cancerformswithpoorprognosis)•  Importantclinicalsafetyandefficacydataexpectedinthenext12months

•  Secondgenera2onan2bodiesdevelopedforautoimmunedisease•  UniqueandstrongIP•  Leadinvestorswithhighcompetenceandstrongtrackrecord•  Managementandchairmanwithsolidcompetenceinclinicaldevelopment

3

SourceIMSHealth

CAGR6.9% CAGR7.5-10.5%

Lead project CAN04 in the highest growth segment– Oncology an,bodies

World’smostsoldcancerdrugsarean1bodies(2016)Rituxan/MabThera $8.58bnAvas1n $6.75bnHercep1n $6.75bn

Immuno-oncologydrivingmarketgrowth(2016)Opdivo $3.77bn ($0.94bn)Keytruda $1.40bn ($0.57bn)

4

Cantargia at a glance •  Specializedinan2bodytherapy/immunology,with

ini2alfocusononcology•  GrantedIPontherapeu2ctargetanddrugcandidates•  Leadan2bodyCAN04inclinicalstagefromQ32017•  Strongmanagementteamwithproventrackrecordin

clinicaldevelopmentandbusinessdevelopment•  IPOMarch2015(NasdaqFirstNorth,Stockholm)•  Appr3000shareholdersinclspecialistandstronglong

terminvestors•  BasedinLund,Sweden

Financialhighlights•  Shareprice:6.20SEK(0.77USD),Aug23,2017•  Marketcap:199MSEK(24.6MUSD),Aug23,2017•  Cash:66.5MSEK(8.2MUSD),June302017

Currentowners(June30,2017)

LUBio 12.6%Sunstone 7.2%AvanzaPension 6.4%DavidOlsson 2.5%BrushamnInvest 2.5%KuduAB 2.4%ThoasFioretos 2.3%MarcusJärås 2.3%MatsInvestAB 2.2%Akademihemman 2.2%Others 57.4%

5

Cantargia pipeline

6

Recent News Flow •  CAN04clinicaltrialapplica2on–regulatoryapproval(July2017)

•  Collabora2onagreementwithPanoramaResearchInc(Sunnyvale,CA)(June2017)onan2bodydevelopmentinautoimmunedisease

•  CAN04patentapplica2on-inten2ontograntbyEPO,no2ceofallowanceUS(April/June2017)

•  CAN04strongsafetydatainGLPstudies(May2017)

7

IL1RAP - a novel target on cancer cells

•  IL1RAPiden2fiedasacancertarget(severalcancerforms)•  IL1RAPregulatesinflamma2on(incl.IL-6andIL-8)•  Cantargia’sleadcandidateCAN04isanan2bodyagainstIL1RAP

IL1RAP

Normal cell Cancer cell

8

CAN04 - immuno-oncology mechanism with an,tumor effect

•  Antitumor effects in NSCLC PDX models •  CAN04 stimulates immune cells to infiltrate tumor

Control CAN04

Cancer cells

Stroma cells

Inflammatory immune cells

Blood vessels

Stromawithinfiltra1ngimmunecells

Iso ty

p e ctr l

C A N 0 40

5

1 0

1 5

2 0

N K 1 .1 + in tu m o r

% N

K1

.1+

tu

mo

r ti

ss

ue p = 0 ,0 0 72

9

0 5 1 0 1 50

5 0 0

1 0 0 0

1 5 0 0

2 0 0 0

2 5 0 0

C A N 0 4 1 0 m g /k g (n = 1 0 )

D a y s

Tu

mo

r v

olu

me

(m

m3

)

V e h ic le

**

C A N 0 4

Is o ty p e c o n tro l

** *

*

CAN04 Clinical Development

•  PhaseI/IIatrial-NSCLCandpancrea2ccancer•  ApprovaltostartinNorwayand

Denmark•  ReviewongoinginBelgiumand

Netherlands•  Adap2vedesign(phaseIIapartfinal

designbasedonphaseIandpreclinicaldata)

•  PhaseIIainleukemia•  PlannedtostartajerphaseIIdose

defined2018

10

CAN04 - Several shots on goal

Focusonthreecancerformswithdifferentbiologicalproper2es,challenges,prognosisandstrategicopportuni2esNextstepdevelopmentcanfocusoncancerform(s)withstrongestefficacysignal

IL1RAP - addi,onal poten,al indica,ons to leverage the value of our asset

•  ThreedifferentsystemssignalthroughIL1RAP•  Thesesystemscontributetovariousinflammatorydiseases•  CanbeblockedbyCantargia’san2bodiesagainstIL1RAP

12

Strategic partnership with Panorama Research Inc PanoramaResearchInc•  Privately-ownedbiomedicalR&DcompanyinSiliconValleyCalifornia

•  Leaderinan2bodytechnology,managedbyDrJamesW.Larrick

Dealstructure:Panoramashareriskinexchangeforafrac2onoffutureincomes

PanoramaResearch,Inc.A Biotechnology Research& DevelopmentCompany

•  CantargiaIL1RAPan2body,affinitymaturedandhumanizedusingPanorama’sproprietarytechnology

•  Panoramaalsogeneratescelllinesop2mizedforhighlevelGMPproduc2on

•  Cantargiaresponsibleforsubsequentdevelopment13

•  Developmentofnewan2bodybindingIL1RAPwithhighaffinity/potentinhibi2onofsignaling•  Focusonautoimmune/inflammatorydisease

•  Selec2onofclinicalcandidate2019

Management

GöranForsbergCEOsince2014,born1963Göran Forsberghas a PhD in biochemistry, and is an associateprofessor andtheauthorofover40scien2ficpublica2ons.Hehasworkedforpharmaceu2caland biotechnology companies for more than 25 years in various posi2ons,includingatKabiGen,Pharmacia,Ac2veBiotechandtheUniversityofAdelaide,Australia.Forsberg’smostrecentposi2onwasChiefBusinessOfficeratAc2veBiotech AB. He has a large amount of drug development experience, with aspecialfocusononcology.Since2011,ForsbergisaboardmemberofIsogenicaLtd.SharesinCantargia:48,350

Liselo]eLarssonVPOpera9onssince2014,born1963Liselope Larsson has a PhD in biotechnology, and has more than 20yearsofexperienceinvariousmanagementposi2onsinpharmaceu2caland biotechnology companies including BioGaia Fermenta2on,NovozymesBiopharmaandCamurus.Larsson'smainfieldsofexper2seare business development, marke2ng & sales/out licensing, ISOcer2fica2on, good manufacturing prac2ce (GMP) and overall projectmanagement.SharesinCantargia:15,000

LarsThorssonVPClinicalDevelopmentsince2015,born1961LarsThorssongraduatedwithaPh.D.inclinicalpharmacologyin1998.Thorssonhas more than 25 years experience in the pharmaceu2cal industry, includingleading roles in clinical studies andprojectmanagement in a largenumberofdevelopmentphasesatAstraZeneca.Thorsson’smostrecentlyworkedatNovoNordiskA/S,whereheheld the roleof Senior Clinical Pharmacology Scien2st,responsible for prepara2on and implementa2on of clinical pharmacologicalstudies indevelopmentprojects.Thorssonhasbeenresponsibleforevalua2onand documenta2on of new substances and has the experience of regulatoryac2vi2esandinterac2onswithhealthauthori2es.SharesinCantargia:24,998

DavidLibergVPCancerResearchsince2015,born1969David Liberg graduated with a Ph.D. in 2001 and has nearly twentyyearsofresearchexperiencewithinimmunologyandtumourbiology.Liberghasworkedwithinthepharmaceu2cal industryforthelasttenyears,with responsibility for early research projects and ac2vi2es intumourimmunology.Hehasextensiveexperienceofpre-clinicalphasecancer projects. His most recent posi2on was at Ac2ve Biotech AB,where he worked as ProjectManager Drug Development as well asHead of Cell Biology and Biochemistry. Liberg has also carried outresearchatImperialCollegeintheUKandatLundUniversity,Sweden.SharesinCantargia:2,000

14

BengtJöndellCFOsinceMay2017,born1960.Bengt Jondell has a BSc in Business Aministra2on and a MSc in Chemicalengineering. Jondell has extensive experience in various execu2ve financialfunc2ons such as CFO and Chief Execu2ve Officer at BTJ Group AB, SeniorFinancial Advisor for BoneSupport, CFO/Administra2ve manager at Inpac,BusinessControlleratPharmacia&UpjohnConsumerHealthcare,Pharmacia,PharmaciaConsumerPharmaandPharmaciaNicorepe. Jondell´smost recentposi2onwasCFOforEnzyma2caAB.SharesinCantargia10,000

Board of Directors

MagnusPerssonChairmanoftheBoardsince2016,born1960MagnusPerssonisMDandassociateprofessor inphysiologyatKarolinskaIns2tutetinStockholm.Perssonhasalargeamountofexperienceinthefieldsofmedicine,lifesciences and biotech-financing. Persson has previously led development teams inclinical phase II and phase III programmes in the pharmaceu2cal industry and hasfoundedandledprivateaswellaspublicbiotechandmedtechcompanies,eitheraschairman ormember of the board, in Europe and theUSA. Persson has also beeninvolvedinmul2pleIPOs.SharesinCantargia:28,110and85,000op2ons

LarsH.BruzeliusBoardmembersince2013,born1943Lars H. Bruzelius is an associate professor in Business Administra2on andmanagement consultant with many years of experience working with banks andcompanies in theenergy,medtechand telecommunica2on industries.Bruzelius isaseniorpartner inand jointownerofBSI&Partners,andhasbeenaboardmemberand chairman of LU Bioscience AB since 2012. For three years, Bruzelius was theDeputyChiefExecu2veandAdministra2veDirectorofGambroAB.Bruzeliushasbeenaboardmemberoftwolistedcompaniesaswellasaninvestorandboardmemberofanumberofstart-upcompanies.SharesinCantargia792,577

KarinLeanderssonBoardmembersince2016,born1972Karin Leandersson is associate professor and lecturer in tumourimmunology at themedical faculty of LundUniversity. She has gained awide range of cancer research experience in the fields of tumourimmunologyand tumour inflamma2on in solid tumours,mainly inbreastcancer.Leanderssonhasalsoauthoredaround30scien2ficpublica2onsininterna2onaljournals.SharesinCantargia:0

ThoasFioretosBoardmembersince2010,born1962ThoasFioretos isaprofessorandphysicianat theDepartmentofClinicalGene2cs at Lund University. The focus of his research is molecular andfunc2onalstudiesofgene2cchangesinleukaemiaandhowsuchchangescan be used for diagnos2c and therapeu2c purposes. Fioretos hasauthored many scien2fic publica2ons, and is one of the founders ofCantargiaABandbio-ITcompanyQlucoreAB.SharesinCantargia:732,600

ClausAsbjørnAnderssonBoardmembersince2013,born1968ClausAsbjørnAnderssonisapartnerofSunstoneLifeScienceVentures,aholdingcompanymanagingbillion-dollarventurefunds.HehasaMaster’sdegreeinCivilChemicalEngineeringfromTechnicalUniversityofDenmarkand a PhD in Mathema2cal Sta2s2cs from Copenhagen University andHumboldt University of Berlin. Andersson has himself founded fourEuropeanstart-upcompanies,includingtwoinDenmark.HehasbeenwithSunstone Life Sciences since its establishment in 2007, and is an ac2vemember of the Interna2onal Venture Club and advisor to the EuropeanCommission.SharesinCantargia:0

NiclasLundqvistBoardmembersince2016,born1965NiclasLundqvistisaMasterofLawatlawfirmAdvokatbolagetWiklundGustavii.Since1996, he has specialized in legal counselling with companies listed on the SwedishstockmarketorMTF.Lundqvisthasopera2onalexperiencefromboardsofcompanieslisted on the Swedish stock market and companies under the supervision ofFinansinspek2onen.Hispreviousexperienceincludesothertypesoflegalwork,projectmanagement and business development in Corporate Finance at SedermeraFondkommission from 2003 to 2013. Lundqvist is one of the founders of venturecapitalfund'SwedishGrowthFund'.SharesinCantargia:0

15

Signficant value inflec,on points ahead

2017•  Ini2a2onofphaseI/IIatrial•  Preclinicaldataoncombina2ontherapyH12018•  Presenta2onofPhaseIclinicaldata•  Ini2a2onofPhaseIIapor2onoftheclinicaltrial•  Prepara2onsfortheclinicalphaseIIaofleukemia

16

Why invest in Cantargia? •  Focusonimmuno-oncology-thestrongestgrowingpharmaceu9calsegment

•  Takingadvantageofthewellestablishedan9bodytechnologytodesignnoveltargetedpharmaceu9cals

•  Leadcandidatean9bodyCAN04withdoublemechanismofac9onenteringclinicalstagewithmul9plevalueinflec9onpoints2017-2019•  Ini9aldevelopmentinNSCLCandpancrea9ccancer(cancerformswithpoorprognosis)•  Importantclinicalsafetyandefficacydataexpectedinthenext12months

•  Secondgenera9onan9bodiesdevelopedforautoimmunedisease•  UniqueandstrongIP•  Leadinvestorswithhighcompetenceandstrongtrackrecord•  Managementandchairmanwithsolidcompetenceinclinicaldevelopment

17

Investerardagen Stockholm28augus2,2017

09.15-09.35 PAUS - kaffe, te och vatten